Ensacove™ (ensartinib) – New drug approval
December 18, 2024 - The FDA announced the approval of Xcovery’s Ensacove (ensartinib), for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.
Top